魁北克大规模B群脑膜炎球菌疫苗接种中4CMenB疫苗的短期安全性
为应对Saguenay-Lac-Saint-Jean地区高发的B群侵袭性脑膜炎球菌病,魁北克于2014年5月对近6万名≤20岁人群开展4CMenB疫苗大规模接种,并主动监测免疫后不良事件。截至2015年7月17日,目标人群首剂和次剂接种率分别为83%和77%,7天内反应原性特征与早期临床试验一致,但因不良事件导致的缺勤和就医常见,总体短期安全性和风险获益可接受。
要点
- 大规模接种中4CMenB的7天反应原性特征与早期临床试验一致。
- 发热在<2岁儿童中发生率最高,但报告体温≥40℃者仅0.6%。
- 接种后7天内缺勤或就医在首剂后为6.2%、次剂后为9.2%。
核心结论
- 大规模人群监测显示4CMenB疫苗短期总体安全性和风险获益可接受,尤其作为应对地区高发IMD-B的干预措施。
- 监测识别出与早期临床试验一致的7天反应原性特征,但不良事件相关的缺勤和就医常见,影响该疫苗的社会成本。
研究设计与样本
- 在魁北克Saguenay-Lac-Saint-Jean地区开展的大规模疫苗接种运动中对≤20岁目标人群近60,000人进行主动监测。
- 主动监测评估免疫后7天内急性发作的不良事件、不良事件相关缺勤和就医、退热预防及与其他疫苗同时接种的影响。
主要发现
- 截至2015年7月17日,59,098名目标人群中83%接种首剂、77%接种次剂4CMenB。
- 发热在接种后第1-2天于<2岁儿童中发生率最高,但仅0.6%报告体温≥40℃。
- 在<10岁儿童中,≥2剂对乙酰氨基酚预防显著降低首剂和次剂接种后第1-2天的发热发生率。
- 接种后7天内缺勤或就医在首剂后报告率为6.2%、次剂后为9.2%,最常与发热/不适(4.2%)或注射部位反应(3.6%)相关。
临床怎么用
- 在<10岁儿童中可考虑使用≥2剂对乙酰氨基酚预防以降低首剂和次剂接种后第1-2天的发热发生率。
- 应向家长和接种者告知接种后7天内缺勤和就医的常见性及其与发热/不适或注射部位反应的关系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To address a high incidence of serogroup B invasive meningococcal disease (IMD-B) in the Saguenay-Lac-Saint-Jean region, Quebec, Canada, a mass vaccination campaign targeting nearly 60,000 individuals ≤20 years old was launched in May 2014. Because of the limited clinical experience with the four-component meningococcal B vaccine (4CMenB), active surveillance for adverse events following immunization (AEFI) was conducted. This paper reports 4CMenB AEFI surveillance findings. METHODS: Active surveillance assessed AEFIs with acute onset within 7-days post-immunization, AEFI-associated absenteeism and medical consultations, impact of antipyretic prophylaxis and coadministration of other vaccines. RESULTS: By July 17, 2015, 83% and 77% of the 59,098 individuals targeted by the campaign had received a first and a second dose of 4CMenB. The incidence of fever on days1-2 was highest in children <2 years old but only 0.6% reported a temperature ≥40◦C. Among children <10 years old, ≥2doses of acetaminophen prophylaxis significantly reduced fever incidence on days1-2 after dose1&2. Absenteeism or a medical consultation during the 7 days following vaccination was reported by 6.2% of vaccinees post-dose1 and 9.2% post-dose2 and was most often reported in association with fever/malaise (4.2%) or injection site reactions (3.6%). CONCLUSION: Large-scale population-based surveillance identified a 7-day reactogenicity profile consistent with earlier clinical trials with the 4CMenB vaccine but indicating frequent AEFI-associated absenteeism and medical consultations affecting the societal cost of this vaccine. We conclude acceptable vaccine safety and risk-benefit profile overall on the short term, particularly as an intervention to address a high regional incidence of IMD-B.
引用
- De Serres G, Billard MN, Gariépy MC, et al. Short-term safety of 4CMenB vaccine during a mass meningococcal B vaccination campaign in Quebec, Canada. Vaccine. 2018. PMID: 30467063. doi:10.1016/j.vaccine.2018.10.095
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。